The current preclinical pipeline for drug discovery can be cumbersome and costly, which
limits the number of compounds that can effectively be transitioned to use as therapies …

Metastasis is the leading cause of cancer-related deaths, but it is unclear how cancer cells
escape their primary sites in epithelia and disseminate to other sites in the body. One …

Transition‐metal catalysts exhibit great potential as therapeutic agents to inhibit tumor
growth. However, the precise delivery and in situ catalysis are challenging in catalytic …

Background Breast cancer is the most common malignancy in women worldwide. Among
the breast cancer subtypes, triple-negative breast cancer (TNBC) is the most aggressive and …

Cancer therapeutics is evolving to precision medicine, with the goal of matching targeted
compounds with molecular aberrations underlying a patient's cancer. While murine models …

Brain tumors represent the leading cause of disease-related mortality and morbidity in
children, with effective treatments urgently required. One factor limiting the effectiveness of …

Simple Summary Despite the major progress of precision and personalized oncology, a
significant therapeutic benefit is only achieved in cases with directly druggable genetic …

To achieve a systems-based approach to targeting the antioxidant pathway, 1, 4-
naphthoquinone annulated N-heterocyclic carbene (NHC)[bis (1, 3-dimesityl-4, 5 …

Zebrafish provide a unique opportunity for drug screening in living animals, with the fast-
developing, transparent embryos allowing for relatively high-throughput, microscopy-based …

Since an extensive genome research has started, basic principle “one gene—one protein—
one function” was significantly revised. Many proteins with more than one function were …